Chief of Staff · 4D Molecular Therapeutics, Inc. (FDMT)

Theresa Janke

FY2021 is the first fiscal year CompBrief holds for Theresa Janke as a named executive officer of 4D Molecular Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,572,695

Salary $385,000Stock awards $0

3rd of 3 named executive officers at 4D Molecular Therapeutics by FY2021 total.

3 named officers on file for 4D Molecular Therapeutics, FY2021

Theresa Janke’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how 4D Molecular Therapeutics’s whole pay program stands against its peers

  • 4D Molecular Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FDMT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 13, 2022 (DEF 14A).

Free

Get Theresa Janke’s full pay file as a PDF — free

More than this page: up to 10 years of Theresa’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Theresa Janke compensation by year

4D Molecular Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as 4D Molecular Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$385,000
Bonus$0
Stock awards$0
Option awards$2,048,585
Non-equity incentive$129,360
Pension and deferred compensation$0
All other$9,750
Total$2,572,695

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 13, 2022, accession 0001193125-22-104263, and prior-year filings. Open the filing on EDGAR.

How this page was built: the 4D Molecular Therapeutics, Inc. filed document, accession 0001193125-22-104263. Every figure is read from that document and cited to the page and table it appears in. Filed April 13, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option2,500—$3.19
Option56,875—$41.66

Per the Outstanding Equity Awards at Fiscal Year-End table in 4D Molecular Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

4D Molecular Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
David KirnChief Executive Officer$5,200,825
August MorettiChief Financial Officer$2,635,785
Theresa Janke · this pageChief of Staff$2,572,695

The full 4D Molecular Therapeutics compensation record

free company brief

This page is one person within 4D Molecular Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 4D Molecular Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Theresa Janke's compensation dossier · One-time report. No refunds.